Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Kroger cuts same-store sales outlook, keeps earnings guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Progenics' (PGNX) Relistor Setback Only a Speedbump - Jefferies
April 5, 2016 9:34 AM EDTJefferies analyst, Gena Wang, sees the FDA extension for Progenics Pharmaceuticals' (NASDAQ: PGNX) oral Relistor as a timing setback only. No change to Buy rating or $9 PT.
The FDA extended the PDUFA by 3mon (to July 19) for oral Relistor in opioidinduced constipation in... More
Needham & Company Defends Progenics (PGNX) on PDUFA Delay, Valeant Overhang
April 4, 2016 1:23 PM EDTNeedham & Company analyst Chad Messer has come out to defend Progenics Pharmaceuticals (NASDAQ: PGNX), which is down 6.5% after the FDA extended oral Relistor PDFUA by 3 months to July 19th. The FDA made the extension in order to review responses by Valeant to recent... More
